Peter Lebowitz News Today

Check out a roundup of this week’s medical marketing news, executives on the move and industry chatter.

Compared to osimertinib alone, first-line treatment with amivantamab plus lazertinib was also shown to improve progression-free survival and have an increased duration of response.

News Release Media Contacts: Brian Kenney +1 215-620-0111 Suzanne Frost +1...

The MARIPOSA study evaluated amivantamab-vmjw (Rybrevant; Janssen Pharmaceutical) in combination with lazertinib compared to osimertinib and compared to lazertinib monotherapy in the first-line treatment of EGFR-mutated non–small cell lung cancer.

First-line treatment with the combination of amivantamab and lazertinib resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared with osimertinib in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations.

The phase 3 MARIPOSA- 2 study shows significant improvement within progression free survival after implementing Rybrevant into treatment for patients with non-small cell lung cancer.

Patients who received amivantamab plus chemotherapy or amivantamab without chemotherapy presented better outcomes compared to chemotherapy alone.

Amivantamab-vmjw plus carboplatin and pemetrexed, administered with or without lazertinib, significantly improved progression-free survival vs chemotherapy alone in patients with locally advanced or metastatic non–small cell lung cancer with EGFR exon 19 deletions or L858R substitutions after progression on or after osimertinib.

Balversa has been submitted to the FDA for approval to treat patients with locally advanced or metastatic urothelial carcinoma.

News Release Media Contacts: Suzanne Frost Phone: +1 416-317-0304 Ania DiAntonio ...